Navigation Links
Experimental Dengue Vaccine Shows Some Success
Date:9/11/2012

TUESDAY, Sept. 11 (HealthDay News) -- An experimental vaccine may offer protection from dengue fever, a potentially fatal mosquito-borne illness, according to a new study.

The vaccine was safe and effective against three of the four viruses that cause the disease, researchers found in the study, published online Sept. 10 in The Lancet.

Dengue fever occurs in tropical and subtropical areas, according to the World Health Organization. The number of cases has increased significantly in recent years, and in 2009 the disease made a return to the continental United States.

According to the Florida Department of Health, in 2009, 27 people living in Key West came down with illness via locally acquired infections, and then 66 more residents contracted the illness in 2010. The outbreak seems to have eased since then, however.

Dengue symptoms typically appear three days to two weeks after a mosquito bite and can range from mild to incapacitating fever with severe headache, pain behind the eyes, muscle and joint pain, and rash. Severe dengue, which mostly occurs in children, includes fever, abdominal pain, vomiting and bleeding.

"Nearly half a million people are thought to be hospitalized with dengue every year, the majority of which are children, so the development of a safe and effective vaccine has the potential to make a hugely positive impact," study co-author Dr. Derek Wallace of Sanofi Pasteur, the company that developed the vaccine, said in a journal news release.

In conducting the study, researchers in France and Thailand tested the effectiveness of the possible vaccine known as CYD-TDV, on more than 4,000 Thai children ranging in age from 4 to 11 years. Of these children, 2,669 were given the vaccine, while the others received an inactive placebo.

The study found 2.8 percent of the children who received the vaccine were diagnosed with dengue, compared with 4.4 percent among the placebo gro
'/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Standard chemotherapy provides higher survival rate than experimental in lung cancer patients
2. Cancer turns off important immune cells, complicating experimental vaccine therapies
3. Experimental Drug May Cut Severe Asthma Attacks: Study
4. Experimental Drug Suppresses Appetite in Mice: Study
5. Experimental Chemical Helps Blind Mice See
6. Experimental drug may extend therapeutic window for stroke
7. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
8. Content Writing King Announces Cancellation Of Experimental Video Creation Process For Their Article Marketing Website
9. Experimental Vaccine Seems to Stop Nicotine Addiction in Mice
10. Experimental drug improves muscle strength among male cancer patients
11. Experimental Drug Helps Fight Some Childhood Cancers, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Dengue Vaccine Shows Some Success
(Date:7/30/2014)... Dennis Thompson HealthDay Reporter ... people with depression are more likely to develop dementia, but ... the relationship between the two. Specifically, they haven,t been ... works -- does depression help bring on dementia, or does ... published online July 30 in the journal Neurology ...
(Date:7/30/2014)... drug to treat malaria, is now widespread throughout ... ( P. falciparum ) parasites that cause the ... mutation in the parasites. However, a six-day course ... three-day coursehas proved highly effective in treating drug-resistant ... the New England Journal of Medicine . ...
(Date:7/30/2014)... Mozes HealthDay Reporter WEDNESDAY, ... help their preschooler shed excess pounds may want to team ... parents joined them in a supervised behavioral modification program gained ... traditional child-only program (an average difference of about four pounds ... 15 pounds over two years, according to the study. ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 SF Cable, ... at the lowest prices on the internet with guaranteed ... in two lengths and two colors. These lightning cords ... , The high quality SF Cable Lightning ... with digital signal delivering faster charging and syncing. Compatible ...
(Date:7/30/2014)... Lexington, MA (PRWEB) July 30, 2014 ... provider of authentication, access management and secure communications ... Imprivata OneSign ® is the most widely ... using McKesson Paragon or Horizon electronic medical records ... (an increase of about 11 percent in the ...
Breaking Medicine News(10 mins):Health News:Scientists Shed Light on Link Between Depression, Dementia 2Health News:Scientists Shed Light on Link Between Depression, Dementia 3Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2
... Toronto Stock Exchange Symbol: CYT, MONTREAL, May ... cryotherapy products to treat cardiac,arrhythmias, today announced financial results ... Selected Second Quarter Financial and Operational Highlights:, - ... $10.2 million or a 37.6% ...
... N.Y., May 12 Gentiva Health,Services, Inc. (Nasdaq: ... services, announced today that it is scheduled to,present from ... 2008 at the 2008,Citi Investment Research Global Health Care ... available to the public via a live audio web,cast, ...
... IQ more likely the younger a child is at diagnosis, study ... 5 percent of people with multiple sclerosis are diagnosed when they,re ... function, causing memory and attention problems, and possibly low IQ scores. ... of diagnosis, the more likely he or she is to have ...
... even harm cognitive function , , MONDAY, May 12 (HealthDay News) ... daily use of two popular pain-relieving drugs, Celebrex and naproxen, ... history of Alzheimer,s disease. , In fact, naproxen, which goes ... a deleterious effect on cognitive function, the study found. ...
... than 2,000,hospital employees, patients and others concerned about the ... State House today in the "Care,Today, Gone Tomorrow" rally ... Toting signs that read "Some Cuts Never Heal" ... and state lawmakers to restore,the $143 million in charity ...
... Damir Matic, a scientist with Lawson Health Research Institute in ... performed throughout North America and around the world. Matic ... close the gum tissue of cleft palate patients. His research ... is older. , Matic is a craniofacial/plastic surgeon at London ...
Cached Medicine News:Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 9Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 10Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 11Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 12Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 2Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 3Health News:Multiple Sclerosis Affects Children's Cognitive Skills 2Health News:Multiple Sclerosis Affects Children's Cognitive Skills 3Health News:Celebrex, Naproxen Won't Prevent Mental Decline 2Health News:Celebrex, Naproxen Won't Prevent Mental Decline 3Health News:Crowd Rallies to Protest Hospital Cuts 2Health News:Crowd Rallies to Protest Hospital Cuts 3Health News:Crowd Rallies to Protest Hospital Cuts 4Health News:Research shows timing improves cleft palate surgery 2
(Date:7/30/2014)... 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... has announced today that they have received CE ... Device. Velox CD™ provides a safe and predictable ... procedures. The single size velox CD™ is indicated ... 5F to 8F.  Velox CD™ utilizes ...
(Date:7/30/2014)... 2014  InnoPharma, Inc. today announced the first generic ... of Zyprexa® injection), in Canada.  Olanzapine is indicated for ... patients with schizophrenia or bipolar I mania. ... has entered into an agreement with Sandoz Canada Inc., ... use, sell, market and distribute Olanzapine Injection in ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
Breaking Medicine Technology:Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... WIXOM, Mich., Sept. 19 Rockwell Medical,Technologies, ... innovative manufacturer and,developer of concentrates and specialty ... announced today that it has commenced,enrollment in ... Ferric,Pyrophosphate (SFP), a physiological iron-maintenance therapy drug. ...
... ALEXANDRIA, La., Sept. 18 Life Recovery ... an emerging provider of,groundbreaking medical devices for the ... System has been granted European CE,Mark (Conformite Europeene) ... e.g., to induce hypothermia in patients to,preserve cardiac ...
Cached Medicine Technology:Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System 2
... F340 is a basic laboratory system for ... results can be obtained when used with ... electrode. • Fast and easy one and ... for five buffers (pH 1.68, 4.00, 7.00, ...
... the multifunctional high-end microplate reader with outstanding ... modes., Fluorescence Intensity - FRET , ... HTRF, AlphaScreen , Luminescence , ... emission microplate reader with fastest read times. ...
... microplate reader combines improved flexibility ... with a wide range of ... the flexibility, sensitivity and high ... is the ideal detection solution ...
... for Ultra High Throughput Screening (UHTS), ... detection performance. Allows for smooth transfer ... development by sharing all the detection ... fluorescence intensity, fluorescence polarization, time-resolved fluorescence, ...
Medicine Products: